High Society – GW, Bayer and biopiracy

On May 21, 2003, GW Pharmaceuticals, makers of Sativex, a cannabis based medicinal inhalant, announced their 40 million dollar marketing partnership with Bayer. Malmo-Levine looks at the history of Bayer and their criminal activities in all three world wars. Then DML conducts an interview with Ikechi Mgbeoji, professor of Law at UBC, and his opinion on the viability of a cannabis monopoly though pharmaceutical plant patents of existing strains.

The article I wrote on GW that started the GW debate:

http://www.cannabisculture.com/articles/2780.html

Here’s that Bayer Men’s Chorus link:
http://www.baykomm.bayer.de/en/welcome/chor_e.html

Here’s some online video by Bayer about Bayer:

http://www.bayer.com/en/tk/cropscience.php
http://www.bayer.com/en/tk/healthcare.php
http://www.patlore.com/pages/bayer.html

To join in on a discussion of the merger, click here:
http://www.cannabisculture.com/cgi/ubbthreads/showflat.php?Cat=&Board=current&Number=542807&page=1&view=collapsed&sb=5&o=&fpart=2

To join in on a discussion on GW amd plant patents, click here:
http://www.cannabisculture.com/cgi/ubbthreads/showflat.php?Cat=&Board=wwwactive&Number=519200&page=1&view=collapsed&sb=5&o=&fpart=3

Biopirates! Bayer and GW Merger…
-one step closer to a pot monopoly?

21 May 2003 – GW and Bayer Announce Marketing Agreement on Pioneering New Cannabis-based Treatment

GW Pharmaceuticals and Bayer AG have entered into an exclusive marketing agreement for GW’s cannabis-based medicinal extract product, to be marketed under the Sativex® brand name.

Bayer has obtained exclusive rights to market Sativex in the UK. In addition, Bayer has the option for a limited period of time to negotiate the marketing rights in other countries in European Union and selected other countries around the world.

They are teaming up to provide a “medically acceptable cannabis-derived product” for the treatment of MS and severe neuropathic pain. The product is a whole plant medicinal cannabis extract containing THC, or, as GW puts it, “tetranabinex” and CBD, or according to GW, “Nabidiolex” as its principal components. The medicine is administered by means of a spray into the mouth.

Dr Geoffrey Guy, Executive Chairman of GW, said: “We are delighted to have entered into this partnership with Bayer. Having recently submitted the regulatory dossier for Sativex to the UK regulatory authorities, this announcement is a further significant achievement for GW. It is GW’s first commercial collaboration and marks the start of a new phase in the company’s history. As a leading global pharmaceutical company, Bayer is well placed to maximise the market opportunity for GW’s product.”

http://www.gwpharm.com/news_pres_21_may_03.html

“Well placed” is RIGHT. Bayer is currently ranked 6th in chemical sales, first or second in “agricultural chemical” sales, sells about 11 billion dollars worth of “health care” products per year and does about 30 billion – US – in total sales per anum.
(Chemical Week Magazine Oct. 30th, 2002, p. 14; Chemical Market Reporter Jan. 28 2002; and the International Directory of Company Histories, Vol. 41, 2000)

According to Reuters, the drugs and chemicals group will pay GW up to 25 million pounds ($41 million) for exclusive rights to market Sativex in Britain. Dr. Guy told Reuters he was comfortable with analyst forecasts of peak annual sales of 250 million pounds in initial markets of Europe and Canada. Shares in GW shot up on news of the deal.

http://www.reuters.com/newsArticle.jhtml?type=topNews&storyID=2784123

We here at Pot TV want to give you the WHOLE story surrounding the Bayer-GW merger – and that means some background on Bayer, and some details on the patenting of plants. Later on in the show, we’re going to talk to Professor Ikechi Mgbeoji of the University of British Columbia
http://www.law.ubc.ca/faculty/mgbeoji/
about his views on “Biopiracy” – the corporate world’s attempts at patenting medicinal plants formerly held in common, and how it might relate to the Bayer-GW merger.

On GW:

We have provided some links in the info box – both pro-GW and anti-GW, to give you a better understanding of the scope of the debate surrounding this company.

Pro:
http://www.cannabishealth.com/current/apr04p5.htm
http://www.cannabisculture.com/articles/2919.html
http://www.maps.org/media/potpioneer.html

Anti:
http://www.cannabisculture.com/articles/2780.html
http://www.cannabisculture.com/cgi/ubbthreads/showflat.php?Cat=&Board=wwwactive&Number=519200&page=1&view=collapsed&sb=5&o=&fpart=1

It had to be Bayer! Bayer Bayer Bayer.

What luck! I had, just by coincidence, been studying this company all year long. This company has possibly the worst record on human rights and the environment on the planet. I personally see Bayer as the most evil corporation ever.

If it was 20 strikes and you’re out, Bayer would have been gone a long time ago.

Since this is a short show, I’m only going to skimm through some of their worst crimes, as we simply don’t have the bandwidth for a comprehensive show.

The history of Bayer

The link to the sources for this can be found here:
http://www.cannabisculture.com/cgi/ubbthreads/showflat.php?Cat=&Board=terror&Number=496614&page=1&view=collapsed&sb=5&o=&fpart=1

In 1897, a Bayer chemist, Arthur Eichengrün – a Jew – discovered Aspirin. Eichengrün was prolific, with 40 patents to his name and was promoted to the head of pharmaceutical research at Bayer upon his discovery. (8)

Eichengrün was never given credit for discovering Aspirin. When he was promoted head of research, his assistant, German Felix Hoffmann – the man Bayer claims to this day (9) invented aspirin – was moved to the sales department. As it turns out, IG Farben made the Hoffmann story up in 1933 as the Nazi’s came into power. To be fair, Bayer would never forget the inventor of their best seller – “the world’s favorite painkiller”. They used their influence with the Nazi’s to make sure Eichengrün got sent to the best of concentration camps. (10) He even got his own room.
(see also “Most Useful Drug”, Readers Digest, April 1954, p. 68-70)

Bayer also invented Heroin around the same time. Perhaps their only good product in their entire history – nothing better for pain in the world.

In 1916, Bayer chemist Carl Duisberg would organize a loose association of the eight biggest German chemical companies, including Hoechst (the inventors of Novocaine) and BASF (the same BASF that’s on all those audio and video tapes) and formalize this association in 1925, joining with their Swiss counterparts Ciba, Geigy and Sandoz in 1929. (6) From the beginning, the association was called the “Interessen Gemeinschaft der Deutschen Teerfarbenindustrie” – the “Community of Interest of the German Dyestuff Industry” – I.G. Farben for short.

It was Carl Duisberg, head of I.G., a man who “would not tolerate dissent”, a man who “believed in the ‘Fuhrer Principle’ long before Hitler was ever heard of”, it was Duesberg who urged the employment of chemical warfare in the autumn of 1914 (18) – to get the dye industry going again after the war cut into demand. Duesberg “also involved himself personally in the experiments.” (19) Duisberg, on top of being an authoritarian, also had a reputation as an anti-semite. (11) His tenure as head of Bayer ran from before Bayer’s theft of Aspirin until after IG used their Aspirin and Heroin profits to be the top funder of the Nazi party during their most important elections.

On April 22, 1915, when the Germans finally tried out their new weapon – chlorine gas – it was the I.G. companies and I.G. chemists that supplied it. Five thousand died terrible deaths – another 10,000 were wounded. (20) By the end of the war, at least 91 thousand men had died of gas. Another 1.3 million had been wounded by gas…. one of them was being a young soldier named Adolf Hitler. (21) Hitler decided – while recovering from the IG Farben-invented mustard gas – that he would channel his “growing hatred” for those who lost the war by entering politics.

Aside from calling for a “Fuhrer”, gassing millions, and warping young Adolph’s mind, I.G. would set other examples for the Nazis. In 1916, the IG plant managers were calling for “National Socialsim” – again, years before anyone had even HEARD of Adoph Hitler.(27)

In September 1916 – one month after consolidating I.G. – Carl Duesburg came up with yet another vision. He proposed that the war ministry begin the “forced deportation of Belgian workers to German factories”. (29)
The Belgian clergy and journalists filled the world’s newspapers with the horrors of the enslavement. The US government sent their German counterparts a note about the forced labor, complaining of a “contravention of all precedents”. The deported Belgians, now 40,000 strong, refused to work. Faced with worldwide condemnation, the German power structure abandoned their “free-labor” idea (30)… at least until they could figure out a way to avoid worldwide condemnation.

In a 1925 speech to the central organization of German industry – the Reichsverband, Carl Duisberg was quoted as saying –
“If Germany is again to be great, all classes of our people must come to the realization that leaders are necessary who can act without concern for the caprices of the masses…”(33)
To be fair, it was mainly steel companies (34), middle class German patriots and the American pro-Nazi Prescott Bush bank – the “Brown Brothers Harriman” bank – (35) who kept the Nazi’s equipped with snazzy uniforms and torches….until the depression hit in 1929. Fearing a communist election victory, more and more of Germany’s industrialists began to support Hitler. By 1931, IG Farben was doing so too, although not publicly. (36)

Right-wing historians have tried to downplay I.G.’s “several secret contributions to the Nazi war chest” in 1931 and 1932, (37) and up-play I.G.’s resistance (until 1932) to Hitler’s anti-Semitism. (38) Yet this was the depression – a time when everyone was starving and desperate for any job. No specific amount was mentioned, but I.G. was by far the largest corporation in Europe, and any donation was no doubt vital to electoral victory.

In early 1933, right before the Nazi’s last election, four IG representatives showed up at a meeting of German Industrialists and Nazi economic advisors. According to the November 23, 1945 transcripts from Nuremberg war-crimes trial, Hitler and Goering were hitting up the industrialists for election money. Hitler was to have said;

“Now we stand before the last election. Regardless of the outcome there will be no retreat, even if the coming election does not bring about a decision.”

Goering then added; “the sacrifices asked for surely would be so much easier for industry to bear if it realized that the election of March 5th will surely be the last one for the next 10 years, probably even for the next 100 years.” The Nazi’s asked for 3 million marks. They got it, and IG contributed more than ten percent – the largest single contribution. (41)

Once Farben’s Nazi’s bought enough votes to entrench themselves in power, they made well on their election promise to their employers. Beginning with joint Nazi-IG Farben synthetic oil and rubber ventures in 1933 that made Hitler’s war machine self-sufficient, the co-operation continued with the plunder of Europe’s chemical industries. As the Nazi’s invaded each country, I.G. would take control of the chemical companies. (51)

If these “hostile takeovers” were good for business, slavery was even better. Instead of “work rather than phrases”, many of the camps had “work will set you free” on their gates. It was the greatest false-advertising campaign in human history – unless you define “free” as “dead from exhaustion”. As the war dragged on, I.G. created it’s own private camp called Monowitz – also known as Auschwitz III.

Monowitz was located right outside the largest synthetic oil and rubber factory in the world, the largest industrial complex outside the borders of the German Reich, and I.G.’s largest factory: I.G. Auschwitz. I.G. Farben owned 100% of I.G. Auschwitz. The sight had been chosen by I.G. for the abundant water and coal in the area, not to mention all the free slave labor from Auschwitz I and II. (52 ) I.G. created Monowitz because too many of their employees would die while marching to work every day.

The “slaves” at I.G. Auschwitz were quickly worked to death. It was not slave labor, it was death labor. (54)

IG Farben even made a killing off killing. Zyklon B – “Cyclone B” in German – was the name of the gas that the Nazi’s used to kill off scapegoats not lucky enough to be selected for death labor. Zyklon B was sold by Degesch, a company owned (mostly) by I.G. Farben. Degesch profits “doubled” as a result of its Zyklon B sales – they even saved money removing the now-superfluous “warning odor”. (56)

Various I.G. gasses were tested on Auschwitz prisoners. (57) Various I.G. pharmaceuticals were, too. (58) Most died from the experiments themselves – others were eliminated due to concerns of a proprietary nature. Bayer was at the head of the IG Farben “drug-testing program”.
One of the SS doctors at Auschwitz, Dr. Helmut Vetter, a longtime Bayer employee, was involved in the testing of Bayer experimental vaccines and medicines on inmates. He was later executed for giving inmates fatal injections. (59)

Bayer would constantly send “new preparations” to try out on prisoners, and argue over the cost of Ukrainian women as if they were lab mice. (60)

In a number of documents only recently discovered exists a letter in which Bayer Sales Director Wilhelm Mann praised famous Nazi Dr. Joseph Mengele’s experiments and promised to discuss financing from the company. “I have enclosed the first check,” Mann wrote. “Dr. Mengele’s experiments should, as we both agreed, be pursued. Heil Hitler!” Mengele wrote this to his bosses at Bayer headquarters;

“I have thrown myself into my work wholeheartedly, especially as I have the opportunity to test our new preparations. I feel like I am in paradise.” (63)

In 1948, a small minority of the IG Farben directors – all of the eye-witnesses – were found guilty in at Nuremberg of mass murder, enslavement and plunder, including Fritz ter Meer. Because of pressure from right wing legislators in the US (who felt the real enemy was “communism – not German businessmen”) they were all out of jail within four years. (66)

Despite introducing gas warfare, forced labor, National Socialism and the “Fuhrer Principle”, despite encouraging anti-Semitism, despite being the Nazi’s biggest financial backers, they were all acquitted of “preparation and waging of aggressive warfare” and “conspiracy” – the court ruled that there was not enough evidence of “knowledge of the immediate result” of their own actions. (67)
This, despite evidence that “Farben (Bayer) agencies in Chile and Argentina supported, financially and otherwise, the establishment of local chapters of the Nazi Party and the dissemination of propaganda through German chambers of commerce.”
http://www.mazal.org/archive/nmt/07/NMT07-T0133.htm
Anyone who wants to understand the origins of WW2 should read the link provided – it’s the evidence against IG Farben produced at Nuremburg:
http://www.mazal.org/archive/nmt/07/NMT07-C001.htm
The truth is that there was plenty of evidence against them, it’s just that IG Farben was indistinguishable from – and often in business with – the biggest oil, chemical and drug cartels in the United States. That’s why they got off. Had they all been found guilty, war profiteering might have ended – or at least become more difficult. As in WW1, the war trials were a sham.

Bayer’s next racket was vitamin over-regulation.

From 1956-1964, Fritz ter Meer was reinstated as a member of the Managing Board of Bayer AG. In 1962, just fifteen years after a few Farben big-wigs were convicted at Nuremberg of mass murder and plunder, Hoechst, Bayer and BASF established the Codex Alimentarius Commission. (95) One of the main architects of Codex was Fritz ter Meer.

The title “Codex Alimentarius” – Latin for “food code” – is as misleading as “Work will set you free”. Codex isn’t just a list of herbs and some organic certification standards. The recently published proposed draft guidelines for vitamin and mineral supplements of the Codex Alimentarius Commission stipulate that the “maximum level of each nutrient contained in a vitamin and mineral supplement should not exceed 100% of the recommended daily intake”. (96)

Putting it in plain terms, CODEX uses scientific sounding language and alphabetic gibberish to argue for dosage limits, despite the fact that supplements have a better safety record than food. In Germany today, folks can’t even look at a vitamin bottle without permission from a pharmacist! (97)

The full implications of this amount of “Big Brother” health regs are not obvious. It works out to only 65 mg of “legal” vitamin C per day – an absurd limit! Other proposals would make “any product” that has ever been rumored to be used to heal into a “registered drug” requiring a prescription! (98)

Check out this show for more on CODEX:
http://www.pot-tv.net/archive/shows/pottvshowse-916.html

And if you think the CODEX “free trade” Vitamin Scam is scary, you should hear about CIPRO!

Cipro, made by Bayer AG, is the first medication specifically approved for use in the event of a biological attack. A year before 9-11, U.S. health officials approved Cipro to fight “the deadly agent, anthrax”. Cipro was already one of the world’s top-selling antibiotics. (128)

Suspiciously, the Bush cabinet was all put on Cipro on September 11th, 2001 – almost a month before people began dying from anthrax. (129)“One doesn’t simply start taking a powerful antibiotic for no good reason. The American people are entitled to know what the White House staffers knew nine months ago, “ stated one US truth and justice activist. (130)

Amidst anthrax attacks and widespread fears of exposure, Bayer has refused to allow other pharmaceutical firms to produce ciprofloxacin hydrochloride – so that they can sell more Cipro. (131) Activists are now prosecuting a nationwide class action lawsuit on behalf of all persons in the US who purchased or paid for Cipro, accusing Bayer AG of entering into unlawful agreements with Barr Laboratories, Inc. and Hoechst Marion Roussel, Inc. under which, in exchange for over $50 million per year, these two companies agreed not to manufacture or market a generic version. (132)

The U.S. Health and Human Services Secretary Tommy Thompson threatened to override Bayer’s patent unless they agreed to lower the price of the pill, which Bayer promptly agreed. (133) Secretary Thompson ordered more than $100 million worth of CIRPO from Bayer at the “bargain price” of $.90 per tablet, when other companies offered equally effective and lower risk substitutes for a few pennies each, and then for free. No one ever questioned the unprecedented FDA selection of this single, largely untested, extraordinarily expensive, antibiotic called CIPRO for anthrax. Incredibly, according to the Physician’s Desk Reference and American Medical Association, the drug is “contraindicated” – a fancy term for “historically bad drug-effect relationship” or “unwise to use” – for conditions resulting in pneumonia, which is how anthrax kills. (134)

Consider also Cipro’s listed side effects; Abdominal pain; constipation; diarrhea; dizziness; gas; headache; heartburn; lack of energy; loss of appetite; nausea; sensitivity to sunlight; stomach upset; vomiting. Blurred vision; chest pain; chills; fever; hives; nightmares; restlessness; ringing in the ears; skin rash and tremors. (136)

By January 2002, after more than 32,000 people from Washington to Boston consumed CIPRO in the wake of the anthrax mailings, thousands had become seriously ill, many died, as a result. This death toll has never been counted in assessing the damage brought about by the mailings. (137)

Many researchers have noted cannabis’s reputation – mostly in African folk medicine – as an effective remedy for anthrax. (138) The role certain cannabinoids play in general anti-biotic action is more well known. (139) Cannabis – both smoked and infused into a drink – is often used to clean out the lungs. (140)

Nobody has died – nor has anyone suffered ringing, rashes or tremors – from simply smoking cannabis. (141) The side effects are minor, (142) and can be mitigated. (143)

The major print media is totally Rockefeller. Arthur Hays Sulzberger (1891-1968) sat on the board of directors for both the Associated Press and the New York Times (1935-1961). He was also a director of the Rockefeller Foundation. (348) The Rockefellers own Time and Newsweek (349) The Rockefellers are also old business partners with I.G. Farben.
Both Time and Newsweek had cover stories on bio-terror – both stressing Cipro as the best defense against anthrax and both articles carried a date of Oct. 8, probably shipped out a week before – right before the Oct. 4th “first mention” of anthrax in the mass media. (350) Great timing for Bayer’s Cipro sales – no wonder profits have been so good.

Farben is also involved with the Smallpox vaccine scam, (146, 147) and other bio-weapons scams, mostly run out of their Berkeley “Miles Cutter” lab. (181-184) Bayer is also still in the poison gas business. It has now come out that 200 tons of a basic chemical substance for the neurotoxin VX has disappeared from Iraq’s armaments. The patent for the chemical warfare agent VX comes from Bayer. (185)

Like I said, these crimes are just some of the highlights of Bayer’s long history of genocidal, biocidal crimes – a more comprehensive list is provided in the info-box below:
http://www.corporatewatch.org.uk/profiles/bayer/bayer5.htm

And lets not forget the medicine monopoly.

Big drug companies began by selling analgesics – like Bayer’s Methadone and Heroin. (251) Homegrown cannabis and poppies can be used to treat day-to-day pain concerns without the need to pay Bayer anything – and that’s a big reason why the war on drugs continues.

The August-September 1946 edition of “Ciba Symposia” – the trade magazine of Ciba pharmaceuticals – was entirely devoted to hashish. (323)This must have been printed immediately after the end of WW2. Why 1946? Was it a good deed to make-up for all the years of death and destruction?

For whatever reason it was printed, the cover of the magazine is quite positive, suggesting some of cannabis’s pleasurable and inspirational effects. Depicted is a plant and a hookah, and from the smoke of the hookah comes music, peacock feathers, naked dancing women, the sea, the mountains and the cosmos.

Naked … dancing … women. See? They know exactly what cannabis is all about – fun, joy, appreciation, sensuality, social activity and inspiration.

Novartis, the Swiss side of I.G. Farben, (326) has a website with “health information”, some of it mentioning the various clinical trials being done with dronabonal (synthetic cannabis-like medicine) at the Mayo Clinic (327), the University of Arizona (328), and in the UK (329) The problem with judging the whole plant medicine by observing the effects of isolated synthetic cannabinoids are many. The whole plant provides “complementary cannabinoids” that balance each other out – that just doesn’t exist in the synthetics. (330)
Bayer understands this problem, which is why they went with GW – who are using whole plant medicine yet still are attempting patents on their “delivery technologies” and even on strains of cannabis itself.

Bayer and BASF have both recently announced plans to invest heavily in agricultural bio-tech. (334) The recent Aventis-Bayer merger – put Bayer in the #1 or #2 spot on the short list of “Gene Giants” – the others being Syngenta, Dow and DuPont, (339) – all related to Farben at one time or another. (340) I wrote back in march of this year that “If GW Pharmaceutical ever gets control of the cannabis market through patents and/or inventions (342), no doubt the Gene Giants will buy them out.” It seems like I was right.
There was some debate between myself and super-activist Matt Elrod on the likelyhood of a “marijuana monopoly” arising from GW’s plant patents. Here is an interview I did earlier this week with Ikechi Mgbeoji, Law professor at University of British Columbia
http://www.law.ubc.ca/faculty/mgbeoji/
about his views on “Biopiracy”.

Well, that’s our show for this week. The message is, don’t trust GW – definately don’t trust their new business partners Bayer (worst corporation on earth) and fight any monopoly and any plant patents you can however you can. I leave you with these two quotes from two long-time cannabis activists.

“The forces keeping pot illegal are among the strongest in the world. They include the oil and petrochemical industries, liquor and tobacco companies, and the pharmaceutical industry. … the truth is legalizing hemp would restructure our national economy and put more money in the hands of American farmers, while devastating the petrochemical industry – the major source of world pollution. They have billions of dollars and all the thugs and narco cops on their side, but the truth is on our side. One day the truth will prevail.”
-Steve Hagar, High Times publisher, Interview in High Times magazine, July 1990 (359)

“Remember, there is a ‘THEY’ and ‘THEY’ ARE out to get you. ‘THEY’ are the petrochemical pharmaceutical military-industrial trans-national fascist corporate elite son-of-a-bitches. … and ‘THEY’ look at the Constitution and the Bill of Rights as impediments to the implementation of their “New World Order” … the war against marijuana … the war against this natural plant is their attempt to keep the farmers, the people … and folks like you and me out of power ….”
– Gatewood Galbraith, “High Society” interview with David Malmo-Levine, Pot TV, 26 Oct. 2001 (360)

http://www.gwpharm.com/news_pres_21_may_03.html
21 May 2003
GW and Bayer Announce Marketing Agreement on Pioneering New Cannabis-based Treatment
GW Pharmaceuticals plc (“GW”) and Bayer AG (“Bayer”) have entered into an exclusive marketing agreement for GW’s cannabis-based medicinal extract product, to be marketed under the Sativex® brand name.
Bayer has obtained exclusive rights to market Sativex in the UK. In addition, Bayer has the option for a limited period of time to negotiate the marketing rights in other countries in European Union and selected other countries around the world.
The financial terms of this partnership have been established to yield equal long term value to each partner. GW has maintained a significant share of long term product revenues whilst benefiting from a signature fee, an innovative advance working capital facility and milestone payments in the near term to further enhance GW’s cash position.
The medicine has been developed by GW to provide a medically acceptable cannabis-derived product for the treatment of the debilitating symptoms of Multiple Sclerosis (MS) and severe neuropathic pain. The product is a whole plant medicinal cannabis extract containing tetranabinex (Tetrahydrocannabinol (“THC”)) and Nabidiolex (cannabidiol (“CBD”)) as its principal components. The medicine is administered by means of a spray into the mouth.
GW submitted a product licence application for Sativex to the UK Medicines and Healthcare Products Regulatory Agency (“MHRA”) in March 2003.
Sativex and a THC medicine are also undergoing Phase III trials for the treatment of cancer pain. If approved, Bayer will also market these medicines for cancer pain.
In addition to a share of product revenues, GW has received a signature fee and will receive additional fees on regulatory approval in the UK of the initial indications of MS, neuropathic pain and cancer pain, totalling £25 million. In the event that Bayer exercise the option for countries outside the UK, additional milestones shall be payable on a country by country basis.
Of the £25 million milestone payments, £10 million can be drawn by GW in advance as an interest-free working capital facility to support ongoing preparations for market launch of Sativex. The facility can be drawn by GW at GW’s discretion until MHRA approval is obtained. On approval, Bayer has the option to convert the facility into a milestone payment or to convert into GW shares at an agreed premium to the share price at the time of conversion. The facility is subject to additional conditions if MHRA approval is not obtained by 30 September 2004.
GW is to be responsible for commercial product supply and has entered into a supply agreement with Bayer. GW will manage the supply of product through a range of contract manufacturing partners, arrangements for which are all in place.
Dr Geoffrey Guy, Executive Chairman of GW, said: “We are delighted to have entered into this partnership with Bayer. Having recently submitted the regulatory dossier for Sativex to the UK regulatory authorities, this announcement is a further significant achievement for GW. It is GW’s first commercial collaboration and marks the start of a new phase in the company’s history. As a leading global pharmaceutical company, Bayer is well placed to maximise the market opportunity for GW’s product.”
Commenting on the commercial terms of the agreement between the two companies, Dr Guy added: “GW’s commercial strategy is to maximise the value of its products by entering into agreements at a late stage of development. The terms of this agreement reflect the merits of this strategy. Most importantly, GW retains a significant interest in revenues from product sales.“
Dr. Christa Kreuzburg, Head of Europe for Bayer HealthCare’s Pharmaceuticals Division, said: “We are delighted that GW has selected Bayer as its marketing partner to bring this innovative medicine to market. Supporting medical professionals with effective therapies for the management of MS and severe neuropathic pain is an area of largely unmet need. I am therefore very excited that Bayer will be bringing a product to market with the potential to make a significant contribution in this area. Our two companies are now working closely to prepare for market launch in the UK. Sativex will enhance our portfolio in the UK extremely well and strengthen the market position of Bayer Pharmaceuticals”.
– Ends –
Notes to editors:
Bayer HealthCare, a forthcoming subgroup of Bayer AG, is one of the world’s leading innovative companies in the health care and medical products industry. More than 34,000 employees work for Bayer HealthCare worldwide.
Bayer HealthCare combines the global activities of the Animal Health, Biological Products, Consumer Care, Diagnostics and Pharmaceuticals divisions. Our work at Bayer HealthCare is to discover and manufacture innovative products for the purpose of improving human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.
Enquiries:
GW Pharmaceuticals plc (21/05/03) 44 20 7067 0700
Dr Geoffrey Guy, Executive Chairman (Thereafter) 44 1980 557000
Justin Gover, Managing Director
Mark Rogerson, Press and PR 44 7885 638810

Weber Shandwick Square Mile 44 20 7067 0700
Kevin Smith

Bayer AG 49 214 30 66102
Christina Sehnert

Bayer plc 44 1635 563607
Sylvia Barber

http://www.news.bayer.com/News/News.nsf/id/2003-0229
Wednesday – May 21, 2003

Bayer and GW Pharmaceuticals announce marketing agreement on pioneering new cannabis-based treatment

Leverkusen – Bayer AG and GW Pharmaceuticals plc (GW) have entered into an exclusive marketing agreement for GW’s cannabis-based medicinal extract product, to be marketed under the Sativex® brand name. Bayer has obtained exclusive rights to market Sativex in the UK. In addition, Bayer has the option for a limited period of time to negotiate the marketing rights in other countries in European Union and selected other countries around the world. GW submitted a product licence application for Sativex to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in March 2003.
The medicine has been developed by GW to provide a medically acceptable cannabis-derived product for the treatment of the debilitating symptoms of Multiple Sclerosis (MS) and severe neuropathic pain. The product is a whole plant medicinal cannabis extract containing tetranabinex (tetrahydrocannabinol – THC) and nabidiolex (cannabidiol – CBD) as its principal components. The medicine is administered by means of a spray into the mouth.

Sativex and a THC medicine are also undergoing Phase III trials for the treatment of cancer pain. If approved, Bayer will also market these medicines for cancer pain.

“We are delighted that GW has selected Bayer as its marketing partner to bring this innovative medicine to market. Supporting medical professionals with effective therapies for the management of MS and severe neuropathic pain is an area of largely unmet need. I am therefore very excited that Bayer will be bringing a product to market with the potential to make a significant contribution in this area. Our two companies are now working closely to prepare for market launch in the UK. Sativex will enhance our portfolio in the UK extremley well and strengthen the market position of Bayer pharmaceuticals”, said Dr. Christa Kreuzburg, Head of Europe for Bayer HealthCare’s Pharmaceuticals Division.

Dr Geoffrey Guy, Executive Chairman of GW, said: “We are delighted to have entered into this partnership with Bayer. Having recently submitted the regulatory dossier for Sativex to the UK regulatory authorities, this announcement is a further significant achievement for GW. It is GW’s first commercial collaboration and marks the start of a new phase in the company’s history. As a leading global pharmaceutical company, Bayer is well placed to maximise the market opportunity for GW’s product.”

The financial terms of this partnership have been established to yield equal long term value to each partner. In addition to a share of product revenues, GW has received a signature fee and will receive additional fees on regulatory approval in the UK of the initial indications of MS, neuropathic pain and cancer pain, totalling £25 million. In the event that Bayer exercise the option for countries outside the UK, additional milestones shall be payable on a country by country basis.

Of the £25 million milestone payments, £10 million can be drawn by GW in advance as an interest-free working capital facility to support ongoing preparations for market launch of Sativex. The facility can be drawn by GW at GW’s discretion until MHRA approval is obtained. On approval, Bayer has the option to convert the facility into a milestone payment or to convert into GW shares at an agreed premium to the share price at the time of conversion. The facility is subject to additional conditions if MHRA approval is not obtained by 30 September 2004.

GW is to be responsible for commercial product supply and has entered into a supply agreement with Bayer. GW will manage the supply of product through a range of contract manufacturing partners, arrangements for which are all in place.

Forward-looking statements
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Gas Warfare:
http://www.ga.k12.pa.us/academics/us/TECHsite/WWIsite/WWImedia/WWIimages/imagesGas/imageGas1.gif
http://www.ga.k12.pa.us/academics/us/TECHsite/WWIsite/WWImedia/WWIimages/imagesGas/imageGas2.gif
http://www.ga.k12.pa.us/academics/us/TECHsite/WWIsite/WWImedia/WWIimages/imagesGas/imagePostcardGasMasks.gif
http://www.ga.k12.pa.us/academics/us/TECHsite/WWIsite/WWImedia/WWIimages/imagesGas/imageGas104151.gif
http://www.ga.k12.pa.us/academics/us/TECHsite/WWIsite/WWImedia/WWIimages/imagesGas/imageGas114918.gif
http://www.ga.k12.pa.us/academics/us/TECHsite/WWIsite/WWImedia/WWIimages/imagesGas/90494.jpg
http://www.ga.k12.pa.us/academics/us/TECHsite/WWIsite/WWImedia/WWIimages/imagesGas/0501009GasMask.JPG
http://www.ga.k12.pa.us/academics/us/TECHsite/WWIsite/WWImedia/WWIimages/imagesGas/imageGasHorseback.jpg

Hitler in WWI
http://www-cgsc.army.mil/milrev/english/JanFeb01/images/fen4a.jpg
http://www.bbc.co.uk/history/war/wwtwo/images/hitler_soldier_wwi3.jpg
http://www.bbc.co.uk/history/war/wwtwo/images/hitler_crowd2.jpg

Images of : WW2 Concentration Camps.
http://www.mazal.org/Auschwitz Aerial/Farben-06-26-44.htm
http://www.mazal.org/Auschwitz Aerial/Buna-01-14-45.htm
http://www.gandhi.edu.uy/cci/imagen.htm
http://histoireenprimaire.free.fr/images/auschwitz.jpg
http://www.denktag.de/denktag2001/projekte/29/auschwitz.jpg
http://history.binghamton.edu/hist486q/pages/images/auschwitz.jpg
http://www.library.cornell.edu/okuref/auschwitz.jpg
http://www.holocaust-uddannelse.dk/images/billeder/auschwitz-birkenau05.jpg
http://www.auschwitz-muzeum.oswiecim.pl/html/eng/start/foto/brama-auschwitz.jpg
http://www.celan-projekt.de/bilder/gefangene-auschwitz.gif
http://www.leksikon.org/images/auschwitz.jpg
http://www.pangea.org/publicpr/auschwitz.gif
http://tfn.net/holocaust/online/auschwitz.gif
http://together.net/~wbaker/auschwitz.gif
http://www.holocaust-uddannelse.dk/images/billeder/auschwitz-birkenau02.jpg

Mengele
http://www.hwrc.org/inthespirit/images/photo/36.jpg
http://more.abcnews.go.com/media/OnAir/images/abc_mengele990611_t.jpg
http://www.gesch.med.uni-erlangen.de/gewissen/ausstell/zwill/_bild/23_25.jpg
http://www.shoa.de/pictures/p_josef_mengele2.gif
http://www.hwrc.org/inthespirit/images/photo/37.jpg
http://www.wordwiseweb.com/AUSCHWITZ/AUSCHWITZ/auschwitzGIFS/twins.jpeg
http://www.leksikon.org/images/auschwitz.jpg

Dr. Guy
http://www.pharmj.com/Editorial/19991120/clinical/cannabistrials.html
http://www.cannabisculture.com/articles/2919.html

Codex
http://indypgh.org/uploads/vitamins.jpg
http://www.lef.org/magazine/mag99/images/jan99-forum.jpg
http://www.lef.org/shop/picts/codex.gif
http://www.dr-rath-vitamins.com/images/news/demo.gif

Vitamins
http://www.healthleadsuk.com/acatalog/vitamins.jpg
http://www.rodaleinstitute.org/kids/tour_1/tour1_images/vitamins.gif
http://www.radiationoncology.net/art/vitamins.jpg

Cipro
http://www.bayerhealth.com/images/inf-cipro.jpg
http://pubs.acs.org/cen/images/7945/7945NOTW3.Cipro.JPG
http://www.wbur.org/special/specialcoverage/images/2002/0102cipro.jpg
http://www.el-mundo.es/especiales/2001/10/internacional/libertad/images/anthrax/cipro.jpg
http://www.1-cipro-antibiotic-medication-4-anthrax-resistance.com/pics/stop.gif
http://news.bbc.co.uk/olmedia/1605000/images/_1606542_cipro150.jpg
http://www.aeronautics.ru/archive/vif2_project/photos01/afghan_0083.jpg
http://www.aeronautics.ru/archive/vif2_project/photos01/afghan_0084.jpg
http://www.wtkg.com/common/terror/gfx/cdc_cipro.jpg
http://www.motherjones.com/web_exclusives/features/news/images/cipro.jpg
http://www.cdlr.tamu.edu/dentist/cipro.jpg
http://image.pathfinder.com/time/europe/magazine/20011029/011029cipro.jpg
http://members.aol.com/swparra/images/cipro.gif

Cannabis
http://www.marijuanaaddiction.info/images/cannabis field small.jpg

“Among the industries to which special consideration should be given is that of the manufacture of dyestuffs and related chemicals. Our complete dependence upon German supplies before the war made the interruption of trade a cause of exceptional economic disturbance. The close relation between the manufacturer of dyestuffs, on the one hand, and of explosives and poisonous gases, on the other, moreover, has given the industry an exceptional significance and value. Although the United States will gladly and unhesitatingly join in the program of international disarmament, it will, nevertheless, be a policy of obvious prudence to make certain of the successful maintenance of many strong and well-equipped chemical plants. The German chemical industry, with which we will be brought into competition, was, and may well be again, a thoroughly knit monopoly capable of exercising a competition of a peculiarly insidious and dangerous kind.”
-President Wilson, Message of the President of the United States, addressed to both Houses of Congress at the beginning of the first session of the 66th Congress, 1919, p. 8.
http://www.mazal.org/archive/nmt/07/NMT07-T0106.htm

A. Farben and the establishment of the Third Reich

Von Schnitzler went back and reported what he had heard to the other Farben officials. Farben contributed 400,000 marks for Hitler’s campaign – the largest single contribution by any of the firms represented at the meeting. The payment was made on 27 February 1933. The next day the Reichstag building was set on fire, and on the same day Hitler and his Cabinet, utilizing the fire as a pretext, promulgated a decree suspending the constitutional guarantees of freedom. By this decree, certain sections of the German constitution were indefinitely suspended and, as the decree stated:’
“* * * restrictions on personal liberty, on the right of free expression of opinion, including freedom of the press, on the right of assembly and the right of association, and violations of the privacy of postal, telegraphic, and telephonic communications, and warrants for house-searches, orders for confiscations as well as restrictions on property, are also permissible beyond the legal limits otherwise prescribed.”
This was the first act of the man and the party after receiving the subsidy which Farben had so generously provided. The decisive election was held with the constitutional guarantees in a state of suspension one week later; the Nazi Party received seventeen million votes out of thirty-nine million cast, and 288 Reichstag seats out of a total of 647. Still lacking a majority, Hitler applied the “other methods” which he had threatened to use in the speech which von Schnitzler had heard on the 20th of February. Opposition members in the Reichstag were taken into “protective custody” and, in their enforced absence, the Reichstag, on 24 March 1933, passed the Enabling Act which gave Hitler full legislative power, including the power to deviate from the constitution. Thus perished democracy and liberty in Germany; the Third Reich had come to stay for twelve long and terrible years.

Were the defendants shocked, disappointed, or even surprised at the swift and brutal course of dictatorship? In April 1933, Hermann Goering founded the Gestapo. In that same month, the Reich Association of German Industry, of which Carl Duisberg was a founder and Farben a member, submitted to Hitler a plan for the reorganization of German industry according to the “Fuehrerprinzip” or “leadership principle.” In transmitting the plan, Gustav Krupp von Bohlen stated that:”
“The turn of political events is in line with the wishes which I myself, and the board of directors, have cherished for a long time. In reorganizing the Reich Association of German Industry, I shall be guided by the aim of bringing the new organization into agreement with the political aims of the German Government.”
In July 1933, a law was passed declaring the NSDAP to be the only political party, and making it criminal to maintain or form any other political party. Three days earlier, representatives of the Du Pont Company of Delaware met with Carl Bosch, then chairman of the Farben Vorstand, who told them that:
“Just now it is a question of fascism and bolshevism, and industry must support the present government to prevent further chaos. In the beginning, Hitler did not consult industrial leaders, but in recent weeks he has shown his stability by curbing the more extreme elements of the Party and by bringing the industrial leaders into consultation with him.”
What did Farben regard as “stability”? And what was it that seemed to them preferable to “chaos”? During the remaining months of 1933, the grip of tyranny grew even tighter. The independence of the judiciary was fatally undermined, special political courts were established, and the concentration camp made its appearance. Jews were eliminated from the civil service and otherwise persecuted, the trade unions were strangled, and the Hitler Youth was organized on military lines. Joseph Goebbels established the Ministry of Public Enlightenment and Propaganda to insure distortion and suppression of the truth. Within Goebbel’s Ministry, Walther Funk established a “National Advertising Council of the German Economy” [Werberat der Deutschen Wirtschaft], on which the defendants von Schnitzler, Mann, and Gattineau were pleased to serve. Germany withdrew from the International Disarmament Conference and from the League of Nations. Germany’s foreign policy was “ratified” by a so-called “election” in November 1933. At the same “election,” the defendant Schmitz, as a Nazi nominee, was elected to the Reichstag. As government turned into dictatorship, and Germany set her feet on the road to war, Farben became ever more closely integrated with, and vital to, the Third Reich, which it had helped to create.
http://www.mazal.org/archive/nmt/07/NMT07-T0125.htm

Please check out my super cool website:

potshotzine.com

It’s especially for activists and people who want to know the nitty gritty on the herb. The most recent issues were the “Ancient History” issues – sure to please.

Comments